Dr. Reddy's Laboratories Limited (DRREDDY)
Outcome of Board Meeting
Press Release - Q2FY27
- Unaudited consolidated and standalone financial results approved for quarter and half-year ended September 30, 2026
- License and service income includes Rs 529 million from Bendamustine HCL US territorial rights sale and Rs 976 million from biosimilar milestones in Russia
- Provision of Rs 2,230 million for Semaglutide inventory due to API issues
- Discontinued CAR-T R&D programs led to Rs 1,350 million net loss in Q4FY26
- Company expects full recoverability of receivables and assets despite geopolitical uncertainties
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 DRREDDY — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add DRREDDY to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Dr. Reddy's Laboratories Limited
Important.
The summary above is generated automatically from Dr. Reddy's Laboratories Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.